Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: A microdialysis study

Journal of Neuroscience

Volumn 22, Issue 3, 2002, Pages 1034-1041

  Nieto, Magdalena Mas ^a   Wilson, Jodie ^b   Cupo, Annie ^b   Roques, Bernard P ^a   Noble, Florence ^a,c  

^a Laboratoire de Pharmacochimie   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cholecystokinin; Enkephalin; Hippocampus; Microdialysis; Morphine dependence; Nucleus accumbens; Periaqueductal gray matter; Reward

Indexed keywords

CHOLECYSTOKININ; ENKEPHALIN; METENKEPHALIN; MORPHINE; OPIATE; PREPROENKEPHALIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONDITIONING; CONTROLLED STUDY; EMOTION; EXTRACELLULAR SPACE; HIPPOCAMPUS; IMMUNOREACTIVITY; IN VIVO STUDY; LONG TERM CARE; MALE; MICRODIALYSIS; MOLECULAR INTERACTION; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; REINFORCEMENT; REWARD; WITHDRAWAL SYNDROME;

EID: 0036470663     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-03-01034.2002     Document Type: Article

References (65)

1. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats
2. Delta-opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin-like material by subchronic morphine in rats
3. Enkephalin may mediate euphoria and drive-reduction reward
4. Opiate-like action of methionine-enkephalin in inhibiting morphine abstinence syndrome
5. Drinking-induced alterations in reward pathways: An in vivo autoradiographic analysis
6. Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats
7. A heroin-, but not cocaine-expecting, self-administration state preferentially alters endogenous brain peptides
8. A cyclic AMP- and phorbol ester-inducible DNA element
9. Opioid receptor-G protein interactions: Acute and chronic effects of opioids
10. Detection of methionine-enkephalin at the 10 (-16) mole level
11. Opioid and CCK systems in anxiety and reward
12. Drug addiction as dopamine-dependent associative learning disorder
13. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
14. The selective CCK-B antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in rat
15. Heroin and cocaine intravenous self-administration in rats. Mediation by separate neural systems
16. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia
17. Increase of preproenkephalin mRNA in the caudal part of periaqueductal gray by morphine withdrawal in rats: A quantitative in situ hybridization study
18. Time course of morphine withdrawal and preproenkephalin gene expression in the periaqueductal gray of rats
19. Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation
20. Endogenous opioids implicated in the dynamics of experimental drug addictions: An in vivo autoradiographic analysis
21. Self-administration of methionine enkephalin into the nucleus accumbens
22. Functional anatomy of the ventral limbic system-innervated striatum
23. Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms
24. Endogenous opioid systems and alcohol addiction
25. Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway
26. Acute and chronic morphine modifies the in vivo release of methionine enkephalin-like immunoreactivity from the cat spinal cord and brain
27. Drugs of abuse: Anatomy, pharmacology and function of reward pathways
28. Drug abuse: Hedonic homeostatic dysregulation
29. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys
30. Biobehavioral bases of the reinforcing properties of opiate drugs
31. Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas
32. Changes in hypothalamic preproenkephalin A mRNA following stress and opiate withdrawal
33. Role of different brain structures in the expression of the physical morphine withdrawal syndrome
34. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
35. Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA
36. Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats
37. Molecular and cellular basis of addiction
38. Naltrexone in the treatment of alcoholism: A clinical review
39. Repeated heroin administration increases extracellular opioid peptide-like immunoreactivity in the globus pallidus/ventral pallidum of freely moving rats
40. Microdialysis reveals a morphine-induced increase in pallidal opioid peptide release
41. Opioid antagonists in the treatment of alcohol dependence: Clinical efficacy and prevention of relapse
42. The effects of naltrexone on alcohol and cocaine use in dually addicted patients
43. Dissociation of tolerance and dependence to morphine: A possible role for cholecystokinin
44. Accurate measurement of cholecystokinin in plasma
45. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats
46. Association of enkephalin catabolism inhibitors and CCK-B antagonists: A potential use in the management of pain and opioid addiction
47. Oral ethanol self-administration in the rat: Effect of naloxone
48. Naltrexone and relapse prevention treatment for cocaine-dependent patients
49. A neural substrate of prediction reward
50. Forskolin induces preproenkephalin and preprodynorphin mRNA in rat striatum as demonstrated by in situ hybridization histochemistry
51. The dopamine hypothesis of reward: Past and current status
52. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study
53. Brain endorphins: Possible role in reward and memory formation
54. Met-enkephalin alteration in the rat during chronic injection of morphine and/or midazolam
55. Delayed occurrence of enhanced striatal preprodynorphin gene expression in behaviorally sensitized rats: Differential long-term effects of intermittent and chronic morphine administration
56. Cholecystokinin-immunoreactive boutons in synaptic contact with hippocampal pyramidal neurons that project to the nucleus accumbens
57. The CCK-B antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats
58. Decreases in endogenous opioid peptides in the rat medullo-coerulear pathway after chronic morphine treatment
59. The effect of depolarization on expression of the human proenkephalin gene is synergistic with cAMP and dependent upon a cAMP-inducible enhancer
60. Opioids, reward and addiction: An encounter of biology, psychology, and medicine
61. Basal release of Metenkephalin and neurotensin in the ventrolateral periaqueductal gray matter of the rat: A microdialysis study of antinociceptive circuits
62. CI 988, a selective antagonist of cholecystokinin-B receptors, prevents morphine tolerance in rats
63. Effect of opioid peptides on dopamine release from nucleus accumbens after repeated treatment with methamphetamine
64. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in rat spinal cord